Clinical Evaluation of the XDR-LFC Assay for the Molecular Detection of Isoniazid, Rifampin, Fluoroquinolone, Kanamycin, Capreomycin, and Amikacin Drug Resistance in a Prospective Cohort.
Humans
Kanamycin
Isoniazid
/ pharmacology
Capreomycin
Amikacin
/ pharmacology
Rifampin
/ pharmacology
Fluoroquinolones
/ pharmacology
Microbial Sensitivity Tests
Prospective Studies
Mycobacterium tuberculosis
Bacterial Proteins
/ genetics
Drug Resistance, Multiple, Bacterial
/ genetics
Antitubercular Agents
/ pharmacology
Tuberculosis, Multidrug-Resistant
/ diagnosis
Extensively Drug-Resistant Tuberculosis
/ diagnosis
Mycobacterium tuberculosis
amikacin
capreomycin
drug susceptibility
drug-resistant tuberculosis
fluoroquinolone
isoniazid
kanamycin
lateral-flow cell
rifampin
Journal
Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564
Informations de publication
Date de publication:
23 03 2023
23 03 2023
Historique:
pubmed:
10
2
2023
medline:
28
3
2023
entrez:
9
2
2023
Statut:
ppublish
Résumé
While the goal of universal drug susceptibility testing has been a key component of the WHO End TB Strategy, in practice, this remains inaccessible to many. Rapid molecular tests for tuberculosis (TB) and antituberculosis drug resistance could significantly improve access to testing. In this study, we evaluated the accuracy of the Akonni Biosystems XDR-TB (extensively drug-resistant TB) TruArray and lateral-flow-cell (XDR-LFC) assay (Akonni Biosystems, Inc., Frederick, MD, USA), a novel assay that detects mutations in seven genes associated with resistance to antituberculosis drugs:
Identifiants
pubmed: 36757183
doi: 10.1128/jcm.01478-22
pmc: PMC10035299
doi:
Substances chimiques
Kanamycin
59-01-8
Isoniazid
V83O1VOZ8L
Capreomycin
11003-38-6
Amikacin
84319SGC3C
Rifampin
VJT6J7R4TR
Fluoroquinolones
0
Bacterial Proteins
0
Antitubercular Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0147822Subventions
Organisme : NIAID NIH HHS
ID : R44 AI138903
Pays : United States
Organisme : NIGMS NIH HHS
ID : R44 GM103053
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI135756
Pays : United States
Organisme : NIBIB NIH HHS
ID : R44 EB011274
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007384
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI111435
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201600024C
Pays : United States
Références
N Engl J Med. 2010 Sep 9;363(11):1005-15
pubmed: 20825313
Am J Respir Crit Care Med. 2019 Mar 15;199(6):784-794
pubmed: 30252496
J Clin Microbiol. 2021 Feb 18;59(3):
pubmed: 33298611
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32817085
J Clin Microbiol. 2018 Feb 22;56(3):
pubmed: 29305543
Eur Respir J. 2020 Sep 17;56(3):
pubmed: 32430421
J Clin Microbiol. 2018 Apr 25;56(5):
pubmed: 29540456
J Infect Dis. 2019 Oct 8;220(220 Suppl 3):S126-S135
pubmed: 31593599
Anal Chem. 2020 Apr 7;92(7):5311-5318
pubmed: 32142258
J Clin Tuberc Other Mycobact Dis. 2022 Feb 22;27:100304
pubmed: 35252594
BMC Microbiol. 2015 Oct 19;15:220
pubmed: 26483194
J Virol Methods. 2014 Nov;208:152-9
pubmed: 25066276
Biomed Microdevices. 2012 Feb;14(1):45-53
pubmed: 21909803
N Engl J Med. 2018 Oct 11;379(15):1403-1415
pubmed: 30280646
PLoS One. 2018 Jul 5;13(7):e0199869
pubmed: 29975759
Lab Chip. 2019 Mar 27;19(7):1217-1225
pubmed: 30801596
JMIR Res Protoc. 2021 Jul 14;10(7):e26748
pubmed: 34259165
Clin Infect Dis. 2016 May 1;62(9):1081-8
pubmed: 26839383
Lancet Microbe. 2022 Apr;3(4):e265-e273
pubmed: 35373160
Genome Med. 2019 Jun 24;11(1):41
pubmed: 31234910